Matrix metalloproteinases in acute coronary syndromes: a new therapeutic target?
Although matrix metalloproteinase (MMP) expression is found to be elevated after acute coronary syndrome (ACS), the slow elevation of MMP levels and the lack of clinical outcome data do not currently make MMPs useful biomarkers for therapeutic decision making or risk stratification in ACS. They do, however, remain an active area of investigation as a therapeutic target.
Celik
Turgay
T
Iyisoy
Atila
A
Kardesoglu
Ejder
E
Bugan
Baris
B
Isik
Ersoy
E
D054058:Acute Coronary Syndrome / Q000097:blood* / Q000188:drug therapy / Q000201:enzymology*; D015415:Biomarkers / Q000097:blood; D016503:Drug Delivery Systems / Q000379:methods*; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D006801:Humans; D020782:Matrix Metalloproteinases / Q000097:blood*
D015415:Biomarkers; D004791:Enzyme Inhibitors; D020782:Matrix Metalloproteinases